Pre-op eltrombopag reduces need for platelet transfusions

Pre-op eltrombopag reduces need for platelet transfusions
For patients with chronic liver disease who require an invasive procedure as part of their routine care, the oral thrombopoietin-receptor agonist eltrombopag reduces the need for platelet transfusions, but also results in an increased incidence of portal-vein thrombosis, according to a study published in the Aug. 23 issue of the New England Journal of Medicine.

(HealthDay)—For patients with chronic liver disease who require an invasive procedure as part of their routine care, the oral thrombopoietin-receptor agonist eltrombopag reduces the need for platelet transfusions, but also results in an increased incidence of portal-vein thrombosis, according to a study published in the Aug. 23 issue of the New England Journal of Medicine.

Nezam H. Afdhal, M.D., from the Beth Israel Deaconess Medical Center in Boston, and colleagues randomly assigned 292 patients with and of less than 50,000 per cubic millimeter to receive either eltrombopag (75 mg daily) or for 14 days before a planned elective , performed within five days of receiving the last dose.

The researchers found that platelet transfusion (before, during, and up to seven days after surgery) was avoided in 104 of 145 patients who received eltrombopag and in 28 of 147 who received placebo (72 versus 19 percent; P < 0.001). There were no significant differences in bleeding episodes of World Health Organization grade 2 or higher, which were reported in 17 percent of the eltrombopag group and 23 percent of the placebo group. Six patients receiving eltrombopag had thrombotic events of the portal venous system, compared with one patient who received placebo, which triggered early termination of the study. Other adverse events were similar in incidence and severity between the groups.

"Eltrombopag reduced the need for platelet transfusions in patients with chronic who were undergoing elective invasive procedures, but it was associated with an increased incidence of portal-vein thrombosis, as compared with placebo," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including GlaxoSmithKline, which funded the study and manufactures eltrombopag.

More information: Full Text (subscription or payment may be required)

Related Stories

Drug Boosts Platelets in Hepatitis C Patients

Nov 29, 2007

It's not a cure, but this may be some of the best news patients infected with the hepatitis C virus (HCV) have heard in a long time: A new drug, eltrombopag, appears to be effective in boosting low platelet counts, one of ...

Vitreolytic ocriplasmin resolves vitreomacular traction

Aug 16, 2012

(HealthDay) -- Intravitreal injection of the vitreolytic agent ocriplasmin resolves vitreomacular traction and closes macular holes significantly better than placebo, but with a higher incidence of adverse ...

Recommended for you

Recorded Ebola deaths top 7,000

19 hours ago

The worst Ebola outbreak on record has now killed more than 7,000 people, with many of the latest deaths reported in Sierra Leone, the World Health Organization said as United Nations Secretary-General Ban ...

Liberia holds Senate vote amid Ebola fears (Update)

Dec 20, 2014

Health workers manned polling stations across Liberia on Saturday as voters cast their ballots in a twice-delayed Senate election that has been criticized for its potential to spread the deadly Ebola disease.

Evidence-based recs issued for systemic care in psoriasis

Dec 19, 2014

(HealthDay)—For appropriately selected patients with psoriasis, combining biologics with other systemic treatments, including phototherapy, oral medications, or other biologic, may result in greater efficacy ...

Bacteria in caramel apples kills at least four in US

Dec 19, 2014

A listeria outbreak believed to originate from commercially packaged caramel apples has killed at least four people in the United States and sickened 28 people since November, officials said Friday.

Steroid-based treatment may answer needs of pediatric EoE patients

Dec 19, 2014

A new formulation of oral budesonide suspension, a steroid-based treatment, is safe and effective in treating pediatric patients with eosinophilic esophagitis (EoE), according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.